SORT BY Relevancy
MONDAY, NOVEMBER 12, 2012 (3:30 pm PST/6:30 pm EST)
We are excited to present a Reach2HD update from the following amazing individuals:
Dr. Martha Nance is the Director of the HD COE. She is a co-author of “The Physician’s Guide to HD” and “The Juvenile HD Handbook”, and a past member of the Executive Committee of the Huntington Study Group. She is a member of the Steering Committee of Predict-HD and Enroll-HD, and has been a participant in many HD clinical research trials over the last 20 years.
Sarah Janicki is an Assistant Professor in the Department of Neurology at Columbia University Medical Center. Dr. Janicki spent part of her fellowship training in the HDSA Center of Excellence at Columbia, and was happy to rejoin the staff there in early 2011 as a faculty member. Her research involves the effects of hormones and gender on neurodegenerative disorders.
Ronda Clouse, RN joined the HD team at Columbia in 2004. She has 25 years of research experience working with cognitively impaired neurological and psychiatric patients. She provides general support for several HD research protocols and the HD Center clinic, and Coordinates the Reach2HD study at Columbia, New York.
Carlos Singer MD is the Chief of the Division of Movement Disorders at the University of Miami He has chaired one of the working groups for the Parkinson Study Group and has been a member of the Education Committee of the Huntington Study Group. He directs the Huntington Clinic at the University of Miami and has participated in observational and clinical trials of Huntington disease.
Amy Duffy has been a study coordinator specializing in Neurological Movement Disorders at the Mayo Clinic in Arizona for the last 4 years.
MONDAY, June 25, 2012 - 3:30 pm PST/6:30 pm EST
Tonight - an update from our amazing Huntington Study Group (HSG) Reach2HD clinical trial Principal Investigator (PI) Dr. Ray Dorsey and Dr. Caroline Herd, Chief Development Consultant from Prana Biotechnology.
Reach2HD is a study to discover whether PBT2 (an investigational drug) is safe and effective and to determine PBT2's effect on cognition (thinking abilities) and other symptoms including movement and overall functioning.
Tune in for a very informative update on Reach2HD another Huntington Study Group clinical trial.
MONDAY, March 18, 2013
Topics that will be focused on are:
Our therapeutic strategy ‘MPAC’ technology, what are these compounds like PBT2? Brief historical background as to where our HD program came from. A bit of science (although without AV this will be brief indeed) Why we are hopeful that the mechanism of action may provide patient benefit. In particular our previous work with PBT2 in AD. Outline of Reach2HD, status.
MONDAY, MARCH 26, 2012
Reach2HD is a Huntington's disease research trial sponsored by the Huntington's Study Group and Prana Biotechnology to study whether PBT2 (an investigational drug) is safe and effective and to determine if its effect on cognition and other symptoms including movement and overall function.
Study requirements include 8 in-person visits over 6 months and examinations at no cost to you. If you have early to mid-stage Huntington's disease, are at lease 25 years old and if you have a study partner who can come with yo to some of the research visits, this study is for you!
Visit: www.WeHaveAFace.org/hsg for more invormation or go to www.huntington-study-group.org. Call: 800-489-7671 if you want to talk to someone about this study. This study is also available in Australia.
Jody Goldstein has a very long list of accomplishments: BS in Biology from the University of California, San Diego (UCSD), 10 years as coordinator for the UCSD Huntington's Disease Clinical Research Center (HDCRC), Genetically Handicapped Persons Program (GHPP), facilitator for the San Diego Huntington's Disease Support Group and serves as Study Coordinator for more than 18 Huntington's disease clinical studies, 21 publications in peer reviewed journals... the list goes on and she's bilingual working with the local Hispanic HD community.
Everyone should tune in for some very good information about the HSG Reach2HD clinical trial with Jody Goldstein and Elise Kayson from the Huntington Study Group (HSG).
Don't forget to click 'Follow' on our show page and send this link to all your colleagues, friends and family.
Thank you for listening to Help 4 HD - The HD View programs!